New JAMA study supports 2013 guidelines on statin therapy for patients at...
New data published in the Journal of the American Medical Association JAMA supports 2013 guidelines
View ArticleGlobal Statin Market 20152019
Recently added to the BioPortfolio report storeGlobal Statin Market 20152019 is a new report fromTechnavio published on 20150707.This 81page reportis available in pdffrom $2500.About Statin Statin is a...
View ArticleTwo JAMA studies justify increased use of statins
Michael JohnsenThe new guidelines have been expected to increase the number of statineligible adults by almost 13 million.read more
View ArticleFH Common Undertreated in ACS Patients
The estimates of FH in ACS are three to six times higher than in the general population according to a registry report and these highrisk patients remained undertreated with statin therapy. Heartwire...
View ArticleBroader Statin Use Shown To Be Cost Effective And Save Lives. Will This...
Statins are remarkable drugs in the war against heart disease the worlds leading killer. Its time to incorporate them more broadly in healthcare.
View ArticleStatinAssociated Muscle Symptoms Impact on Statin Therapy
Statinassociated muscle symptoms are one of the principal reasons for statin nonadherence. What's the plan when patients don't tolerate statins European Heart Journal
View ArticleDrug Discovery Spotlight Studies Support Broader Statin Use; HCV Meds...
Two years ago cardiology organizations issued guidelines recommending use of a tool to assess patients risk of heart attack or stroke. The new method came under scrutiny but this week two published...
View ArticleStatin Cost Effectiveness Underscored In JAMA Study
Study by researchers at Harvard analyzes the costeffectiveness of statins in patients at low risk of cardiovascular disease under current cholesterol guidelines.
View ArticleStatin Overuse Risky Warns Association of American Physicians and Surgeons AAPS
TUCSON Ariz. July 20 2015 GLOBE NEWSWIRE Two studies published in the July 14 issue of JAMA support new guidelines that could nearly double the number of Americans taking statin drugs to prevent...
View ArticleDr. Nathan D. Wong to Deliver Opening Lecture at International Academy of...
Asher Kimchi M.D. Founder and Chairman of the International Academy of Cardiology today announced the selection of Nathan D. Wong Ph.D. MPH Professor and Director Heart Disease Prevention Program...
View ArticleUse of controversial ACCAHA guidelines for statin therapy is supported by US...
Controversial guidelines for lipid lowering statin therapy issued by the American College of Cardiology ACC and the American Heart Association AHA in 2013 do a better job of identifying people at...
View ArticleEuropean Commission Approves Amgen's New CholesterolLowering Medication...
THOUSAND OAKS Calif. July 21 2015 PRNewswire &160;Amgen NASDAQAMGN today announced that the European Commission EC has granted marketing authorization for Repatha&8482; evolocumab the first...
View ArticleEU Approves PCSK9 Inhibitor Evolocumab Repatha
As the first PCSK9 inhibitor to make it to market evolocumab is approved in a wide array of patients including the statin intolerant and those unable to get to goal with maximally tolerated statin....
View ArticleNew study 80 of people with established cardiovascular disease significantly...
ST. PAUL Minn. July 21 2015 PRNewswire &160;The first of two cholesterollowering PCSK9 inhibitors Proprotein Convertase SubtilisinKexin type 9 is expected to be approved by the U.S. Food and Drug...
View ArticleEU approves Amgen's PCSK9 inhibitor
Amgen Inc. NASDAQAMGN said the European Commission approved an MAA for Repatha evolocumab to treat several groups of patients with high cholesterol. The approval is the first anywhere for a PCSK9...
View ArticlePrime suggests limited PCSK9 coverage
Pharmacy benefit manager Prime Therapeutics LLC Eagan Minn. suggested Tuesday it may limit access to PCSK9 inhibitors to patients with familial hypercholesterolemia based on an analysis of its claims...
View ArticleEurope first with approval of Amgens cholesterol drug Repatha
Amgen's cholesterol drug Repatha has been given the green light in Europe making it the first in the new PCSK9 inhibitor class approved anywhere in the world.Repatha evolocumab is a human monoclonal...
View ArticleEC approves Amgen's PCSK9 inhibitor
Amgen Inc. NASDAQAMGN said the European Commission approved an MAA for Repatha evolocumab to treat several groups of patients with high cholesterol. The approval is the first anywhere for a PCSK9...
View ArticlePenn study finds link between physician training and brand name prescribing
University of Pennsylvania School of Medicine Physicians in training are twice as likely to order a costly brandname statin used to lower blood cholesterol levels when supervised by senior physicians...
View Article